Google
EOLS 株価分析 — EVOLUS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
EOLS に関するよくある質問
EOLSのPER（株価収益率）は？
EVOLUS INC（EOLS）は現在PER 3,044.52倍で取引されています。
EOLSのROE（自己資本利益率）は？
EVOLUS INCのROEは150.87%です。
EOLSの配当利回りは？
EVOLUS INCの配当利回りは0.00%です。
EOLSの品質スコア（Quality Score）は？
当社のAIはEOLSの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EOLSは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EOLSはどのセクターに属しますか？
EVOLUS INCはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
EOLS AI Analysis Summary
Our AI summary for EOLS: EVOLUS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 3,044.52, ROE of 150.87%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.84
Price
-0.17
(-2.83%)
Day Change
|
|
|---|
EOLS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.84 |
| PBV / Sector |
-13.75 / 3.22
|
| Earning Per Share | -0.64 |
| PE / Sector |
3,044.52 / 29.79
|
| PEG or PE/Growth / Sector |
-203.92 / 0.13
|
| Average 1M Daily Value |
4.54 M
GREAT
|
| Average 1W Daily Value |
3.71 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:47 |
| Symbol | EOLS |
| Name | EVOLUS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 65.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 395.79 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660
Phone: 949 284 4555
Website: https://www.evolus.com
Employees: 350
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
